

DAFTAR PUSTAKA

1. Panduan Prevensi Penyakit Kardiovaskular Arteriosklerosis. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia 2022. 2022. 30–42 P.
2. Aroney CN, Aylward P, Kelly AM, Chew DPB, Clune E, Allan RM, Et Al. Guidelines For The Management Of Acute Coronary Syndromes 2006. Vol. 184, Medical Journal Of Australia. 2006. P. 516–25.
3. World Health Organization. Cardiovascular Diseases (Cvds) Factsheet [Internet]. 2015. Available From: [https://www.who.int/news-room/factsheets/detail/Cardiovascular-Diseases-\(Cvds\)](https://www.who.int/news-room/factsheets/detail/Cardiovascular-Diseases-(Cvds))
4. Hamzah. Laporan Riskesdas 2018 Nasional.Pdf [Internet]. Lembaga Penerbit Balitbangkes. 2020. P. 70–5. Available From: [https://repository.badankebijakan.kemkes.go.id/eprint/3514/1/Laporan Riskesdas 2018 Nasional.Pdf](https://repository.badankebijakan.kemkes.go.id/eprint/3514/1/Laporan-Riskesdas-2018-Nasional.Pdf)
5. Garcia AR, Filipe SB, Fernandes C, Estevão C, Ramos G. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI).Pendoman Tatalaksana Dislipidemia Indonesia (Ed-1). Jakarta : Centra Communication : 2013 .6.
6. Juzar DA. Pedoman Tata Laksana Sindrom Koroner Akut 2024. 2024;5:62. Available From: www.merckmanuals.com/professional/cardiovascular_
7. Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid Study: Implications For Treatment Of Dyslipidemia In Type 2 Diabetes Mellitus. Clin Lipidol. 2011;6(1):9–20.
8. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy Of Fenofibrate And Simvastatin On Endothelial Function And Inflammatory Markers In Patients With Combined Hyperlipidemia: Relations With Baseline Lipid Profiles. Atherosclerosis. 2003 Oct;170(2):315–23.

9. Lee SH, Others. STAFENO Trial: Combination Therapy Vs Monotherapy In Coronary Artery Disease. Clinical Research In Cardiology [Internet]. 2020;109(6):702–10. Available From: <https://Link.Springer.Com/Article/10.1007/S00392-020-01679-Y>
10. Khadijah S, Astuti T, Widaryanti R, Ratnaningsih E. Buku Ajar Anatomi Dan Fisiologi Gangguan Pencernaan. Perpustakaan Nasional : Katalog Dalam Tertibtan (KDT). 2020;1–149.
11. Aritonang J. Faktor Risiko Penyakit Jantung: Faktor Yang Dapat Dimodifikasi Dan Tidak Dapat Dimodifikasi. Jurnal Kesehatan Masyarakat. 2012;6(1):45–52.
12. Nadianto A. Patofisiologi Penyakit Jantung Koroner. Jurnal Kardiologi Indonesia. 2018;39(1):21–7.
13. Samiadi S. Pemeriksaan Penunjang Diagnosis Penyakit Jantung. Jurnal Medika. 2016;12(2):33–9.
14. Wongkar AH, Yalume RAS. Faktor Yang Mempengaruhi Penyakit Jantung Koroner Di Ruangan Poliklinik Jantung RS Bhayangkara TK III Manado. J Health Clin Educ (JOCE). 2019;1(2):45–52.
15. Rampengan SH. Buku Kardiologi FK UI. Badan Penerbit Fakultas Kedokteran Universitas Indonesia. 2014. 118–139 P.
16. Satoto HH. Patofisiologi Penyakit Jantung Koroner. JAI (Jurnal Anestesiologi Indonesia). 2014;6(3):209–24.
17. Johnson C, Al. Et. Risk Factors And Prevention Of Coronary Heart Disease: An Updated Review. J Cardiol Res. 2022;15(3):120–30.
18. Muharram FR, Multazam CECZ, Mustofa A, Socha W, Andrianto, Martini S, Et Al. The 30 Years Of Shifting In The Indonesian Cardiovascular Burden-Analysis Of The Global Burden Of Disease Study. J Epidemiol Glob Health. 2024 Mar;14(1):193–212.

19. Tsao CW, Al. Et, Ferreira-González I, Wahidah S, Hermawatirisa D, Libby P, Et Al. Dasar Patofisiologi Aterosklerosis Dan Penyakit Jantung Koroner. *Circulation*. 15th Ed. 2018;1(1):33.
20. Ferreira-González I. The Epidemiology Of Coronary Heart Disease. *Rev Esp Cardiol (Engl Ed)*. 2014;67(2):139–44.
21. Wahidah S. Penyebab Penyakit Jantung Koroner. *J Kesehatan*. 2018;9(1):22–30.
22. Hermawatirisa D. Patogenesis Penyakit Jantung Koroner. *J Medika*. 2014;10(2):55–63.
23. Libby P, Buring JE, Ridker PM. Atherosclerosis: The Pathogenesis Of A Multifactorial Disease. *N Engl J Med*. 2019;380(2):155–65.
24. Yusuf S, Hawken S, Öunpuu S. Effect Of Potentially Modifiable Risk Factors Associated With Myocardial Infarction In 52 Countries (The INTERHEART Study): Case-Control Study. *Lancet*. 2004;364(9438):937–52.
25. Majid A. Dasar Patofisiologi Aterosklerosis Dan Penyakit Jantung Koroner. *J Kardiologi Indones*. 2017;38(1):11–20.
26. Libby P, Theroux P. Pathophysiology Of Coronary Artery Disease. *Circulation*. 2005;111(25):3481–8.
27. Braunwald E, Bonow RO. Braunwald's Heart Disease: A Textbook Of Cardiovascular Medicine. Vol. 11. Philadelphia: Elsevier; 2019.
28. Amsterdam EA, Wenger NK, Brindis RG, Al. Et. 2014 AHA/ACC Guideline For The Management Of Patients With Non-ST-Elevation Acute Coronary Syndromes. *J Am Coll Cardiol*. 2014;64(24):139–228.
29. Knuuti J, Al. Et. 2023 ESC Guidelines For The Management Of Chronic Coronary Syndromes. *Eur Heart J*. 2023;44(3):231–89.

30. Delima PP, Sriati A, Nur'acni A. Illness Cognition Pada Pasien Dengan Penyakit Jantung Koroner. JNC. 2018;1(1):42–9.
31. Chu LM, Shaefi S, Byrne JD, Alves De Souza RW, Otterbein LE. Carbon Monoxide And A Change Of Heart. Redox Biol [Internet]. 2021;48(July):102183. Available From: <https://doi.org/10.1016/j.redox.2021.102183>
32. Syukri AEDP. Profil Penyakit Jantung Koroner Di Irina F Jantung Rsup Prof. Dr. R. D. Kandou Manado. E-Clinic. 2013;1(1):1–8.
33. Collins SP, Storrow A, Liu D, Jenkins CA, Miller KF, Kampe C, Et Al. Almasdy D, Darwin D, Kurniasih N, Handayani V. Pola Penggunaan ISDN Pada Penderita Angina Pektoris Di Suatu Rumah Sakit Pemerintah Kota Padang. 2021;18(1):167–86.
34. Arnold S V., Bhatt DL, Barsness GW, Beatty AL, Deedwania PC, Inzucchi SE, Et Al. Clinical Management Of Stable Coronary Artery Disease In Patients With Type 2 Diabetes Mellitus: A Scientific Statement From The American Heart Association. Circulation [Internet]. 2020 May 12;141(19):E779–806. Available From: <https://www.ahajournals.org/doi/10.1161/CIR.0000000000000766>
35. Aldiwani H, Mahdai S, Alhatemi G. Microvascular Angina Microvascular Angina : Diagnosis And Management Diagnosis And Management Of Microvascular Angina Evidence Of Myocardial Ischaemia. 2021;
36. Indonesia PDSK. Pedoman Tatalaksana Sindrom Koroner Akut. Edisi Ke-4. Jakarta; 2018.
37. Dokter P, Kardiovaskular S, Ketiga E. Pedoman Tatalaksana Sindrom Koroner Akut Edisi Ketiga. 2015; Available From: <https://www.inaheart.org/Wp-Content/Uploads/2025/10/Pedoman-Tatalaksana-Sindrom-Koroner-Akut-2015.Pdf>

38. Oktaviono YH. Panduan Praktik Klinis Dan Clinical Pathway Penyakit Jantung Dan Pembuluh Darah [Internet]. 2016. Available From: <https://www.inaheart.org/storage/guideline/D0fc9c0365362ca4586f8376e378b023.pdf>
39. Ganiswarna SG, Dkk. Farmakologi Dan Terapi. Vol. 4. Jakarta: Bagian Farmakologi Fakultas Kedokteran Universitas Indonesia; 1995. 584–592 P.
40. Xu H, Al. Et. Impacts Of Clinical Pharmacist Intervention On The Secondary Prevention Of Coronary Heart Disease: A Randomized Controlled Clinical Study. *Front Pharmacol*. 2019;33.
41. Rogers R. Statins. *Chest*. 2014;145(1):13.
42. França-Silva MS, Balarini CM, Cruz JC, Khan BA, Rampelotto PH, Braga VA. Organic Nitrates: Past, Present And Future. *Molecules*. 2014;19(9):15314–23.
43. Medscape. Nitroglycerin IV [Internet]. Medscape; 2019. Available From: <https://www.medscape.com/>
44. Medscape. Clopidogrel [Internet]. Medscape; 2019. Available From: <https://www.medscape.com/>
45. Medscape. Aspirin [Internet]. Medscape; 2019. Available From: <https://www.medscape.com/>
46. Medscape. Atenolol [Internet]. Medscape; 2019. Available From: <https://www.medscape.com/>
47. Medscape. Metoprolol [Internet]. Medscape; 2019. Available From: <https://www.medscape.com/>
48. Tremblay J Marie, Regnerus MD, Educação SDASNDE, Júnior FT, Sanfelice JL, Tavares Júnior F, Et Al. Profil Pasien Pengguna Obat Jantung Koroner Rawat Inap Di RSUD Sultan Syarif Mohammad Alkadrie Pontianak. *Educacao E Sociedade*

- [Internet]. 2016;1(1):1689–99. Available From: [Http://Www.Biblioteca.Pucminas.Br/Teses/Educacao_Pereiraas_1.Pdf%0Ahttp://Www.Anpocs.Org.Br/Portal/Publicacoes/Rbcs_00_11/Rbcs11_01.Htm%0Ahttp://Repositorio.Ipea.Gov.Br/Bitstream/11058/7845/1/Td_2306.Pdf%0Ahttps://Dir.eitoufma2010.Files.Wordpress.Com/2010/](http://Www.Biblioteca.Pucminas.Br/Teses/Educacao_Pereiraas_1.Pdf%0Ahttp://Www.Anpocs.Org.Br/Portal/Publicacoes/Rbcs_00_11/Rbcs11_01.Htm%0Ahttp://Repositorio.Ipea.Gov.Br/Bitstream/11058/7845/1/Td_2306.Pdf%0Ahttps://Dir.eitoufma2010.Files.Wordpress.Com/2010/)
49. Rizqi SA, Widada ST, Martsiningsih MA. Pengaruh Pemberian Jus Buah Naga Merah (*Hylocereus Polyrhizus*) Terhadap Kadar Trigliserida Tikus Putih (*Rattus Norvegicus*) Hiperlipidemia. *Jurnal Teknologi Laboratorium*. 2014;3(2).
50. Jauhari NAP, Andrajati R, Tobing R. Monitoring Efek Samping Nyeri Otot Obat Golongan Statin Pada Pasien RSU Universitas Kristen Indonesia Periode Maret–Mei 2014. *Universitas Kristen Indonesia*; 2014.
51. Zazuli Z, Saidah S, Abdulah R, Lestari K. Drug Related Problems In The Management Of Chronic Kidney Disease With Coronary Artery Disease. *Jurnal Farmasi Klinik Indonesia*. 2015;4(2):141–50.
52. Medscape. Atorvastatin [Internet]. Medscape; 2019. Available From: [Https://Www.Medscape.Com/](https://Www.Medscape.Com/)
53. Putri A, Corina. Keefektifan Pengobatan Simvastatin Dan Fenofibrate Terhadap Kadar Low-Density Lipoprotein Cholesterol Dan Trigliserida Pada Pasien Dislipidemia Di RSUD Dabo Kepulauan Riau. [Semarang]; 2024.
54. Fiévet C, Staels B. Combination Therapy Of Statins And Fibrates In The Management Of Cardiovascular Risk. *Curr Opin Lipidol*. 2009 Dec;20(6):505–11.
55. Katzung BG, Vanderah TW. *Basic And Clinical Pharmacology*. 15th Ed. New York: Mcgraw-Hill Education; 2021. 633–639 P.
56. Chalik R. *Anatomi Fisiologi Manusia*. Jakarta: Kementerian Kesehatan Republik Indonesia; 2016. 260 P.

57. Rahmawati AC, Zulaekah S, Rahmawaty S. Aktivitas Fisik Dan Rasio Kolesterol (HDL) Pada Penderita Penyakit Jantung Koroner Di Poliklinik Jantung RSUD Dr. Moewardi Surakarta. *Jurnal Kesehatan*. 2009;2(1):11–8.
58. Sari DM, Azrimaidaliza, Purnakarya I. Faktor Risiko Kolesterol Total Pasien Penyakit Jantung Koroner Di Rumah Sakit Achmad Mochtar Bukittinggi. *Jurnal Kesehatan Masyarakat*. 2008;4(2):77–81.
59. Harivenkatesh N, David DC, Haribalaji N, Sudhakar MK. Efficacy And Safety Of Alternate Day Therapy With Atorvastatin And Fenofibrate Combination In Mixed Dyslipidemia. *J Cardiovasc Pharmacol Ther* [Internet]. 2014 May 10;19(3):296–303. Available From: <https://journals.sagepub.com/doi/10.1177/1074248413518968>
60. Harumini DRA. Gambaran Penggunaan Obat Simvastatin Dan Fenofibrate Pada Pasien Hiperkolesterolemia Di Klinik MMC (Merdeka Medical Centre) Periode Januari–September 2022. [Denpasar]; 2023.
61. Tarantino N, Santoro F, De Gennaro L, Correale M, Guastafierro F, Gaglione A, Et Al. Fenofibrate/Simvastatin Fixed-Dose Combination In The Treatment Of Mixed Dyslipidemia: Safety, Efficacy, And Place In Therapy. *Vasc Health Risk Manag*. 2017;13:29–41.
62. Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Et Al. Efficacy And Safety Of Fenofibric Acid Co-Administered With Low- Or Moderate-Dose Statin In Patients With Mixed Dyslipidemia And Type 2 Diabetes Mellitus. *American Journal Cardiovascular Drugs* [Internet]. 2010 Apr;10(2):73–84. Available From: <http://link.springer.com/10.2165/10061630-000000000-00000>
63. Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, Et Al. Meta-Analysis Of Safety Of The Coadministration Of Statin With Fenofibrate In Patients With Combined

- Hyperlipidemia. Am J Cardiol [Internet]. 2012 Nov;110(9):1296–301. Available From: <https://linkinghub.elsevier.com/retrieve/pii/S0002914912017043>
64. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Et Al. Combination Therapy Of Statins And Fibrates In The Management Of Cardiovascular Risk. Eur Heart J. 2010;41(2):111–88.
65. Athyros VG, Papageorgiou AA, Athyrou V V, Dimitriadis DS, Pehlivanidis AN, Kontopoulos AG, Et Al. Ezetimibe Added To Statin Therapy After Acute Coronary Syndromes. J Cardiovasc Pharmacol Ther. 2003;7(3):203–12.
66. Rokom. Penyakit Jantung Koroner Di Indonesia. Sehatnegerikukemkesgoid [Internet]. 2021;17(1):86–94. Available From: <https://sehatnegeriku.kemkes.go.id/baca/umum/20210927/5638626/penyakit-jantung-koroner-didominasi-masyarakat-kota/>
67. Nichols GA, Bell TJ, Pedula KL, O’Keeffe-Rosetti M. Medical Care Costs Among Patients With Established Cardiovascular Disease. American Journal Of Cardiology. 2016;118(5):733–9.
68. Tenenbaum A, Fisman EZ. Balanced Pan-PPAR Activator Bezafibrate In Combination With Statin: Comprehensive Lipids Control And Diabetes Prevention? Cardiovasc Diabetol [Internet]. 2012;11(1):1. Available From: Cardiovascular Diabetology
69. Kwon TG, Jang AY, Kim SW, Hong YJ, Bae JH, Lee SY, Et Al. Design And Rationale Of A Randomized Control Trial Testing The Effectiveness Of Combined Therapy With Statin Plus Fenofibrate And Statin Alone In Non-Diabetic, Combined Dyslipidemia Patients With Non-Intervened Intermediate Coronary Artery Disease - STAFE. Trials. 2020;21(1):1–10.

70. T. Global Burden Of Disease Study 2019 (GBD 2019) Results [Internet]. Seattle (WA); 2020. Available From: <https://Ghdx.Healthdata.Org/Record/Ihme-Data/Gbd-2019-Disease-And-Injury-Burden-1990-2019>
71. Group TAS. Effects Of Combination Lipid Therapy In Type 2 Diabetes Mellitus. *N Engl J Med*. 2010;362(17):1563–74.
72. Derosa G, Maffioli P, Sahebkar A, Banach M. Combination Therapy Of Statins And Fibrates In The Management Of Cardiovascular Risk. *Archives Of Medical Science*. 2013;9(2):330–40.
73. (IHME) I For HM And E, Tsao CW, Al. Et, Ferreira-González I, Wahidah S. The Epidemiology Of Coronary Heart Disease. *J Kesehatan*. 2022;67(1):153–639.
74. Sumartini NL, Putra AAN, Prasetya AANPR. POLA PENGGUNAAN OBAT PADA PASIEN CAD (Coronary Artery Disease) RAWAT JALAN DI RUMAH SAKIT X DENPASAR PERIODE 2020. *JIM: Jurnal Ilmiah Mahaganesha*. 2021;1(X):1.
75. Real-World Risk Reduction Of MI With Fenofibrate. *Cardiovasc Diabetol* [Internet]. 2024; Available From: <https://Cardiab.Biomedcentral.Com/Articles/10.1186/S12933-024-02353-5>
76. Effects Of Simvastatin Vs Fenofibrate On Lipid And Inflammation Markers. *Pubmed* [Internet]. 2023; Available From: <https://Pubmed.Ncbi.Nlm.Nih.Gov/14612213/>
77. Yang LPH, Keating GM. Fenofibric Acid. *American Journal Cardiovascular Drugs* [Internet]. 2009 Dec;9(6):401–9. Available From: <http://Link.Springer.Com/10.2165/11203920-000000000-00000>
78. Athyros VG, Papageorgiou AA, Athyrou V V., Demitriadis DS, Kontopoulos AG. Atorvastatin And Micronized Fenofibrate Alone And In Combination In Type 2 Diabetes With Combined Hyperlipidemia. *Diabetes Care* [Internet]. 2002 Jul

- 1;25(7):1198–202. Available From:
<https://Diabetesjournals.Org/Care/Article/25/7/1198/21640/Atorvastatin-And-Micronized-Fenofibrate-Alone-And>
79. Farnier M, Davignon J. Current And Future Treatment Of Hyperlipidemia: The Role Of Statins And Fibrates. *American Journal Of Cardiovascular Drugs*. 2010;10(5):309–23.
80. Pownall HJ, Rosales C, Gillard BK, Gotto AM. High-Density Lipoproteins, Reverse Cholesterol Transport And Atherogenesis. *Nat Rev Cardiol* [Internet]. 2021 Oct 8;18(10):712–23. Available From:
<https://www.nature.com/articles/S41569-021-00538-Z>
81. Ramirez A, Hu PP. Low High-Density Lipoprotein And Risk Of Myocardial Infarction. *Clin Med Insights Cardiol* [Internet]. 2015 Jan 3;9:CMC.S26624. Available From: <http://journals.sagepub.com/doi/10.4137/CMC.S26624>
82. Kim SH, Kang SM, Kim JY, Lee JH, Park HS, Choi DJ, Et Al. Effects Of Combination Therapy With Statin And Fenofibrate In Patients With Mixed Dyslipidemia. *Korean Circ J*. 2010;40(6):257–64.
83. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP, Kakafika AI. Safety And Efficacy Of Long-Term Statin-Fibrate Combination Treatment In Patients With Mixed Hyperlipidemia. *Curr Med Res Opin*. 2003;19(3):203–12.
84. Park MS, Youn JC, Kim EJ, Han KH, Lee SH, Kim SH, Et Al. Efficacy And Safety Of Fenofibrate-Statin Combination Therapy In Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-Blind, Phase IV Study. *Clin Ther* [Internet]. 2021 Oct;43(10):1735–47. Available From:
<https://linkinghub.elsevier.com/retrieve/pii/S0149291821003027>

85. Kim KS, Hong S, Han K, Park CY. Fenofibrate Add-On To Statin Treatment Is Associated With Low All-Cause Death And Cardiovascular Disease In The General Population With High Triglyceride Levels. *Metabolism* [Internet]. 2022;137(September):155327. Available From: <https://doi.org/10.1016/j.metabol.2022.155327>

